U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H15F3N4O3
Molecular Weight 404.3433
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOSUFLOXACIN

SMILES

c1cc(c(cc1F)F)-n2cc(c(=O)c3cc(c(nc32)N4CCC(C4)N)F)C(=O)O

InChI

InChIKey=WUWFMDMBOJLQIV-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29)

HIDE SMILES / InChI

Description
Curator's Comment:: http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf

Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in rats. Human data not available.

Originator

Curator's Comment:: http://adisinsight.springer.com/drugs/800005704 | http://www.chemdrug.com/article/8/3285/16420748.html

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

632966400000
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

632966400000
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

632966400000
Curative
Ozex

Approved Use

It is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections.

Launch Date

664502400000
PubMed

PubMed

TitleDatePubMed
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
1993 Apr
In-vitro activity of quinolones and macrolides against mycobacteria.
1994 Sep
Trovafloxacin is active against Toxoplasma gondii.
1996 Aug
Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
1996 Dec
N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.
1996 Nov
Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.
1996 Oct
[In vitro anti-MAC activities of new quinolones in focus (2)].
1996 Sep
Evaluation of in-vitro and in-vivo antibacterial activity of tosufloxacin tosilate.
2001 Dec
Quinolones alter defense reactions mediated by macrophages.
2001 Feb
Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus.
2001 Mar
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.
2001 Nov
[In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
2002 Dec
Clinical assessment of tosufloxacin tosilate.
2002 Mar
Anaphylaxis due to tosufloxacin tosilate.
2003 Sep
[Molecular epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae in Japan].
2004 May
In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species.
2005 Dec
[Evaluation of efficacy of oral quinolone against Streptococcus pneumoniae AND Haemophilus influenzae with the use of Monte Carlo simulation].
2006 Dec
In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus.
2006 Feb
Azithromycin failure in Mycoplasma genitalium urethritis.
2006 Jul
[Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections].
2007 Apr
[Effectiveness of switch therapy for peritonitis].
2007 Aug
[Susceptibility of clinical isolates from primary care clinics to oral antibacterial agents].
2007 Feb
Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model.
2007 Nov
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
2008 Mar
Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents.
2009
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
Antituberculosis activity of the molecular libraries screening center network library.
2009 Sep
[Intractable pediatric infectious disease: examining the ability of a new drug, tosufloxacin tosilate hydrate for pediatric].
2010 Dec
[Antibiotic susceptibility of blood-borne Streptococcus pneumoniae and efficacy assessment of respiratory quinolones using Monte Carlo simulation].
2010 Feb
[Epidemiological analysis of Streptococcus pneumoniae in Gifu prefecture].
2010 Jun
Legionella pneumophila induces cathepsin B-dependent necrotic cell death with releasing high mobility group box1 in macrophages.
2010 Nov 22
Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines.
2010 Sep 20
Patents

Sample Use Guides

In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Route of Administration: Oral
The MIC90s of tosufloxacin among the 27 isolates of macrolide-resistant Mycoplasma pneumoniae (MRMP) was 0.25 ug/ml and those among the 23 isolates of macrolide-sensitive Mycoplasma pneumoniae (MSMP) was 0.5 μg/ml.
Name Type Language
TOSUFLOXACIN
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
A 67107
Code English
ABBOTT-61827
Code English
TOSUFLOXACIN [INN]
Common Name English
ABBOTT 61827
Code English
1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 7-(3-AMINO-1-PYRROLIDINYL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-, (+/-)-
Common Name English
TOSUFLOXACIN [MI]
Common Name English
(+/-)-7-(3-AMINO-1-PYRROLIDINYL)-1-(2,4-DIFLUOROPHENYL)-6-FLUORO-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID
Systematic Name English
TOSUFLOXACIN [MART.]
Common Name English
TOSUFLOXACIN [USAN]
Common Name English
A 61827
Code English
TOSUFLOXACIN [WHO-DD]
Common Name English
A-67107
Code English
A-61827
Code English
Classification Tree Code System Code
WHO-ATC J01MA22
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
NCI_THESAURUS C795
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
Code System Code Type Description
EPA CompTox
100490-36-6
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
ChEMBL
CHEMBL273348
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
DRUG CENTRAL
2710
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
INN
6242
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
EVMPD
SUB11201MIG
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
NCI_THESAURUS
C80642
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
WIKIPEDIA
TOSUFLOXACIN
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
CAS
100490-36-6
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
FDA UNII
GHJ553KQPS
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY
MERCK INDEX
M10984
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY Merck Index
PUBCHEM
5517
Created by admin on Sat Jun 26 00:33:03 UTC 2021 , Edited by admin on Sat Jun 26 00:33:03 UTC 2021
PRIMARY